Number of aberrations by 11q23 translocation partner and clinically relevant parameters
| . | Number of aberrations . | |||||||
|---|---|---|---|---|---|---|---|---|
| 0 . | 1 . | 2 . | 3 . | 4 . | 5 . | > 5 . | All . | |
| TP group | ||||||||
| 9p22 | 168 (44)* | 75 (49)* | 33 (41)* | 19 (43)* | 7 (28)* | 14 (33)* | 316 (43) | |
| 10p12 | 1 (14)* | 47 (12)* | 19 (13)* | 12 (15)* | 7 (16)* | 5 (20)* | 5 (12)* | 96 (13) |
| 6q27 | 1 (14)* | 17 (4)* | 7 (5)* | 1 (1)* | 9 (21)* | 35 (5) | ||
| 19p13 | 20 (5)* | 3 (2)* | 4 (5)* | 1 (2)* | 1 (4)* | 1 (2)* | 30 (4) | |
| 19p13.1 | 1 (14)* | 20 (5)* | 7 (5)* | 2 (3)* | 1 (2)* | 3 (12)* | 34 (5) | |
| 19p13.3 | 12 (3)* | 7 (5)* | 3 (7)* | 2 (8)* | 1 (2)* | 25 (3) | ||
| 1q21 | 18 (5)* | 3 (2)* | 1 (1)* | 1 (2)* | 1 (2)* | 24 (3) | ||
| 4q21 | 5 (1)* | 2 (1)* | 4 (5)* | 1 (2)* | 1 (4)* | 13 (2) | ||
| 10p11.2 | 5 (1)* | 2 (1)* | 3 (4)* | 2 (8)* | 12 (2) | |||
| 17q21 | 9 (2)* | 1 (1)* | 1 (1)* | 1 (2)* | 12 (2) | |||
| Other | 4 (57)* | 61 (16)* | 26 (17)* | 19 (24)* | 11 (25)* | 4 (16)* | 11 (26)* | 136 (19) |
| 733 | ||||||||
| Sex | ||||||||
| Male | 187 (49)† | 89 (59)† | 35 (44)† | 13 (30)† | 11 (44)† | 23 (53)† | 358 (49) | |
| Female | 7 (100)† | 195 (51)† | 63 (41)† | 45 (56)† | 31 (70)† | 14 (56)† | 20 (47)† | 375 (51) |
| 733 | ||||||||
| Age, y | ||||||||
| < 2 | 4 (57)* | 197 (52)* | 61 (40)* | 39 (49)* | 12 (27)* | 16 (64)* | 15 (35)* | 344 (47) |
| 2-9 | 104 (27)* | 49 (32)* | 29 (36)* | 22 (50)* | 5 (20)* | 10 (23)* | 219 (30) | |
| ≥ 10 | 3 (43)* | 81 (21)* | 42 (28)* | 12 (15)* | 10 (23)* | 4 (16)* | 18 (42)* | 170 (23) |
| 733 | ||||||||
| WBC, ×109/L | ||||||||
| < 20 | 5 (71) | 159 (42) | 76 (50) | 39 (49) | 23 (52) | 16 (64) | 21 (49) | 339 (46) |
| 20-99 | 1 (14) | 115 (30) | 38 (25) | 20 (25) | 14 (32) | 5 (20) | 10 (23) | 203 (28) |
| ≥ 100 | 1 (14) | 97 (25) | 34 (22) | 19 (24) | 7 (16) | 2 (8) | 11 (26) | 171 (23) |
| 713 (97) | ||||||||
| FAB | ||||||||
| M0 | 11 (3)* | 4 (3)* | 2 (3)* | 3 (7)* | 1 (4)* | 2 (5)* | 23 (3) | |
| M1 | 19 (5)* | 12 (8)* | 4 (5)* | 1 (2)* | 3 (7)* | 39 (5) | ||
| M2 | 1 (14)* | 19 (5)* | 7 (5)* | 2 (3)* | 3 (7)* | 32 (4) | ||
| M4 | 2 (29)* | 83 (22)* | 25 (16)* | 12 (15)* | 5 (11)* | 2 (6)* | 5 (12)* | 134 (18) |
| M5 | 4 (57)* | 225 (59)* | 97 (64)* | 54 (68)* | 24 (55)* | 17 (68)* | 25 (58)* | 446 (61) |
| M7 | 4 (1)* | 3 (2)* | 2 (3)* | 4 (9)* | 6 (14)* | 19 (3) | ||
| n.d. | 2 (1)* | 1 (1)* | 1 (1)* | 1 (2)* | 1 (4)* | 1 (2)* | 7 (1) | |
| 700 (95) | ||||||||
| Overall | 7 (1) | 382 (52) | 152 (21) | 80 (11) | 44 (6) | 25 (3) | 43 (6) | 733 |
| . | Number of aberrations . | |||||||
|---|---|---|---|---|---|---|---|---|
| 0 . | 1 . | 2 . | 3 . | 4 . | 5 . | > 5 . | All . | |
| TP group | ||||||||
| 9p22 | 168 (44)* | 75 (49)* | 33 (41)* | 19 (43)* | 7 (28)* | 14 (33)* | 316 (43) | |
| 10p12 | 1 (14)* | 47 (12)* | 19 (13)* | 12 (15)* | 7 (16)* | 5 (20)* | 5 (12)* | 96 (13) |
| 6q27 | 1 (14)* | 17 (4)* | 7 (5)* | 1 (1)* | 9 (21)* | 35 (5) | ||
| 19p13 | 20 (5)* | 3 (2)* | 4 (5)* | 1 (2)* | 1 (4)* | 1 (2)* | 30 (4) | |
| 19p13.1 | 1 (14)* | 20 (5)* | 7 (5)* | 2 (3)* | 1 (2)* | 3 (12)* | 34 (5) | |
| 19p13.3 | 12 (3)* | 7 (5)* | 3 (7)* | 2 (8)* | 1 (2)* | 25 (3) | ||
| 1q21 | 18 (5)* | 3 (2)* | 1 (1)* | 1 (2)* | 1 (2)* | 24 (3) | ||
| 4q21 | 5 (1)* | 2 (1)* | 4 (5)* | 1 (2)* | 1 (4)* | 13 (2) | ||
| 10p11.2 | 5 (1)* | 2 (1)* | 3 (4)* | 2 (8)* | 12 (2) | |||
| 17q21 | 9 (2)* | 1 (1)* | 1 (1)* | 1 (2)* | 12 (2) | |||
| Other | 4 (57)* | 61 (16)* | 26 (17)* | 19 (24)* | 11 (25)* | 4 (16)* | 11 (26)* | 136 (19) |
| 733 | ||||||||
| Sex | ||||||||
| Male | 187 (49)† | 89 (59)† | 35 (44)† | 13 (30)† | 11 (44)† | 23 (53)† | 358 (49) | |
| Female | 7 (100)† | 195 (51)† | 63 (41)† | 45 (56)† | 31 (70)† | 14 (56)† | 20 (47)† | 375 (51) |
| 733 | ||||||||
| Age, y | ||||||||
| < 2 | 4 (57)* | 197 (52)* | 61 (40)* | 39 (49)* | 12 (27)* | 16 (64)* | 15 (35)* | 344 (47) |
| 2-9 | 104 (27)* | 49 (32)* | 29 (36)* | 22 (50)* | 5 (20)* | 10 (23)* | 219 (30) | |
| ≥ 10 | 3 (43)* | 81 (21)* | 42 (28)* | 12 (15)* | 10 (23)* | 4 (16)* | 18 (42)* | 170 (23) |
| 733 | ||||||||
| WBC, ×109/L | ||||||||
| < 20 | 5 (71) | 159 (42) | 76 (50) | 39 (49) | 23 (52) | 16 (64) | 21 (49) | 339 (46) |
| 20-99 | 1 (14) | 115 (30) | 38 (25) | 20 (25) | 14 (32) | 5 (20) | 10 (23) | 203 (28) |
| ≥ 100 | 1 (14) | 97 (25) | 34 (22) | 19 (24) | 7 (16) | 2 (8) | 11 (26) | 171 (23) |
| 713 (97) | ||||||||
| FAB | ||||||||
| M0 | 11 (3)* | 4 (3)* | 2 (3)* | 3 (7)* | 1 (4)* | 2 (5)* | 23 (3) | |
| M1 | 19 (5)* | 12 (8)* | 4 (5)* | 1 (2)* | 3 (7)* | 39 (5) | ||
| M2 | 1 (14)* | 19 (5)* | 7 (5)* | 2 (3)* | 3 (7)* | 32 (4) | ||
| M4 | 2 (29)* | 83 (22)* | 25 (16)* | 12 (15)* | 5 (11)* | 2 (6)* | 5 (12)* | 134 (18) |
| M5 | 4 (57)* | 225 (59)* | 97 (64)* | 54 (68)* | 24 (55)* | 17 (68)* | 25 (58)* | 446 (61) |
| M7 | 4 (1)* | 3 (2)* | 2 (3)* | 4 (9)* | 6 (14)* | 19 (3) | ||
| n.d. | 2 (1)* | 1 (1)* | 1 (1)* | 1 (2)* | 1 (4)* | 1 (2)* | 7 (1) | |
| 700 (95) | ||||||||
| Overall | 7 (1) | 382 (52) | 152 (21) | 80 (11) | 44 (6) | 25 (3) | 43 (6) | 733 |
The number of aberrations indicates total number of aberrations in the karyotype, including 11q23/MLL-rearrangement, percentages per group shown in parentheses (per column).
dx indicates diagnosis; FAB, French American British morphology classification subtype; n.d., not determined; TP, translocation partner; and WBC, white blood cell count.
Significantly different at the P < .01 level (χ2).
Significantly different at the P < .05 level (χ2).